Skip to main content

Lantheus Holdings(LNTH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low72.33
Day High75.65
Open:75.65
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Lantheus Holdings

Select a category then submit the form to load news
GlobeNewswire
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
GlobeNewswire
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
Tipranks
Jefferies Sticks to Their Buy Rating for Lantheus (LNTH)
Tipranks
Analysts’ Top Healthcare Picks: Definium Therapeutics (DFTX), Lantheus (LNTH)
Tipranks
Lantheus Earnings Call Maps Painful Reset Before 2027
Tipranks
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Lantheus (LNTH)
Motley Fool
Lantheus (LNTH) Q4 2025 Earnings Call Transcript
StockStory
Lantheus (NASDAQ:LNTH) Exceeds Q4 CY2025 Expectations
LNTH
GlobeNewswire
Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
StockStory
Lantheus Earnings: What To Look For From LNTH
LNTH
GlobeNewswire
Lantheus to Present at March 2026 Investor Conferences
StockStory
2 Value Stocks to Target This Week and 1 Facing Headwinds
INSE
GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time
StockStory
2 Small-Cap Stocks Worth Investigating and 1 We Avoid
BBCP
Tipranks
Lantheus (LNTH) Receives a Buy from TD Cowen
StockStory
3 Market-Beating Stocks for Long-Term Investors
PLTR
Tipranks
Lantheus closes SPECT business sale to SHINE Technologies
GlobeNewswire
Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
StockStory
2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky
DXCM
Tipranks
TD Cowen Keeps Their Buy Rating on Lantheus (LNTH)
Motley Fool
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year
Motley Fool
This Healthcare Stock Still Commands a Top 3 Portfolio Slot Despite a Steep Slide This Past Year
Motley Fool
Investment Fund Adds $8.6 Million Stake in Norwegian Cruise Line Even as Shares Lag the S&P 500 by 27 Points
StockStory
Spotting Winners: Lantheus (NASDAQ:LNTH) And Medical Devices & Supplies - Imaging, Diagnostics Stocks In Q3
LNTH
StockStory
2 Russell 2000 Stocks with Exciting Potential and 1 We Brush Off
GRC
StockStory
Why Lantheus (LNTH) Stock Is Up Today
LNTH
StockStory
3 of Wall Street’s Favorite Stocks to Keep an Eye On
BRZE
Tipranks
Jefferies Sticks to Their Buy Rating for Lantheus (LNTH)
GlobeNewswire
Lantheus to Present Florbetaben F 18 Data at CTAD 2025
StockStory
Align Technology, Tandem Diabetes, Integra LifeSciences, Lantheus, and Inspire Medical Systems Shares Skyrocket, What You Need To Know
ALGN
StockStory
1 Oversold Stock Ready to Bounce Back and 2 We Avoid
WDFC
StockStory
Lantheus (LNTH): Buy, Sell, or Hold Post Q3 Earnings?
LNTH

Profile

Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.